Janssen obtains FDA approval for Darzalex (multiple myeloma)

Janssen, part of Johnson & Johnson group, has announced it has obtained the FDA approval for Darzalex in combination with Takeda’s Velcade and prednisone as a first-line therapy against multiple myeloma. The approval reflects positive results obtained in the Phase-III Alcyone clinical trial, which has demonstrated that Darzalex reduces the risk of progression or death by 50%.

(Source: Janssen)